Ari-Angel Porgador

Title: Innovations of Ari-Angel Porgador

Introduction

Ari-Angel Porgador is a notable inventor based in Lehavim, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic proteins and antibodies. With a total of four patents to his name, Porgador's work has the potential to impact various medical applications.

Latest Patents

Porgador's latest patents include innovative advancements in fusion proteins with extended serum half-life. These patents detail peptides derived from the NKp44 protein, chimeric peptides, nucleotides encoding the same, and pharmaceutical compositions comprising these elements. Additionally, he has developed methods for extending the biological half-life of proteins of interest. Another significant patent involves anti-PCNA monoclonal antibodies, which exhibit increased binding affinity to cytoplasmic PCNA and block its interaction with NKp44. This invention holds promise for treating diseases associated with elevated expression of NKp44, such as cancer.

Career Highlights

Throughout his career, Ari-Angel Porgador has worked with esteemed institutions, including the National Institute for Biotechnology in the Negev Ltd. and the Ben-Gurion University of the Negev Research and Development Authority. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Porgador has collaborated with notable colleagues, including David Ben-Menahem and Roee Atlas. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Ari-Angel Porgador's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the industry. His work continues to pave the way for advancements in medical treatments and therapeutic applications.